DGHO 2020 - Annual Meeting of the German, Austrian and Swiss Societies of Hematology and Medical Oncology (Virtual Meeting)
Oct 09 - Oct 11, 2020 | BaselSwitzerland
LARVOL is not affiliated with Annual Meeting of the German, Austrian and Swiss Societies of Hematology and Medical Oncology (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 332 abstracts linked to Trials
[VIRTUAL] NEOpredict-Lung: A phase II study of neoadjuvant immunotherapy with nivolumab or nivolumab and Relatlimab in patients with primarily resectable, non-small cell lung cancer
[VIRTUAL] QUAZAR AML-001 Maintenance Therapy Study: Results of an international, randomized, double-blind, placebo-controlled phase 3 study of oral CC-486 in patients with acute myeloid leukemia (AML) in first remission
[VIRTUAL] KarMMa-RW: A real-world study provides data on everyday clinical treatment in repeatedly pretreated patients with relapsed and refractory multiple myeloma (RRMM) in comparison to the results of the KarMMa study
[VIRTUAL] Immunomonitoring under blinatumoma therapy in pediatric patients with BCP-ALL within the AIEOP-BFM 2017 study - an interim analysis
[VIRTUAL] Cassiopeia: A phase 2 study to evaluate the efficacy and safety of tisagenlecleucel as first-line therapy in high-risk children and young adults with B-cell acute lymphoblastic leukemia who are MRD positive at the end of consolidation
[VIRTUAL] Phase I study of MB-CART2019.1, a novel CD20 and CD19 tandem chimeric antigen receptor, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
[VIRTUAL] RE-MIND: A Comparison of Tafasitamab + Lenalidomde (L-MIND) vs Lenalidomide Monotherapy ('Real World' Data) in Patients with Relapsed / Refractory Diffuse Large B-Cell Lymphoma
[VIRTUAL] Correlation of bridging therapy (BT) and lymphodepleting chemotherapy (LDC) with clinical outcomes in patients (pts) with relapsed / refractory diffuse large B-cell lymphoma (r / r DLBCL) treated with Tisagenlecleucel
[VIRTUAL] Long-term results of the phase II L-MIND study: tafasitamab (MOR208) + lenalidomide in patients with relapsed / refractory diffuse large B-cell lymphoma
[VIRTUAL] ENGOT-EN6 / GOG-3031 / NSGO-RUBY: A randomized, double-blind, multicenter phase III study with dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in relapsed or primarily advanced endometrial cancer (EC)
[VIRTUAL] Capmatinib in patients with METex14-mutated or highly MET-amplified advanced non-small cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study
[VIRTUAL] Durvalumab with / without bevacizumab as adjuvant therapy in HCC patients with a high risk of relapsing after curative therapy: EMERALD-2
[VIRTUAL] Perioperative chemotherapy with gemcitabine plus cisplatin versus direct radical liver resection for gallbladder carcinoma after simple cholecystectomy or before radical resection for BTC - a phase III study based on the "Central Register of Incidental Gallbladder Carcinoma"
[VIRTUAL] Trifluridine / tipiracil in patients with metastatic colorectal cancer in routine clinical practice in Germany: interim results of the non-interventional study TACTIC
[VIRTUAL] First interim results from Hyperion, a non-interventional study on atezolizumab (Atezo) monotherapy of locally advanced or metastatic non-small cell lung cancer (mNSCLC) after previous chemotherapy (CTx)